Last reviewed · How we verify
Cenicriviroc in mild liver impaired
Cenicriviroc in mild liver impaired is a Small molecule drug developed by Tobira Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: CVC.
At a glance
| Generic name | Cenicriviroc in mild liver impaired |
|---|---|
| Also known as | CVC |
| Sponsor | Tobira Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cenicriviroc in mild liver impaired CI brief — competitive landscape report
- Cenicriviroc in mild liver impaired updates RSS · CI watch RSS
- Tobira Therapeutics, Inc. portfolio CI
Frequently asked questions about Cenicriviroc in mild liver impaired
What is Cenicriviroc in mild liver impaired?
Cenicriviroc in mild liver impaired is a Small molecule drug developed by Tobira Therapeutics, Inc..
Who makes Cenicriviroc in mild liver impaired?
Cenicriviroc in mild liver impaired is developed by Tobira Therapeutics, Inc. (see full Tobira Therapeutics, Inc. pipeline at /company/tobira-therapeutics-inc).
Is Cenicriviroc in mild liver impaired also known as anything else?
Cenicriviroc in mild liver impaired is also known as CVC.
What development phase is Cenicriviroc in mild liver impaired in?
Cenicriviroc in mild liver impaired is in Phase 1.
Related
- Manufacturer: Tobira Therapeutics, Inc. — full pipeline
- Also known as: CVC
- Compare: Cenicriviroc in mild liver impaired vs similar drugs
- Pricing: Cenicriviroc in mild liver impaired cost, discount & access